RNS No 3665j
PALL CORPORATION 
13th November 1997

( BW)(PALL)(PLL) Chinese Ministry of Public Health Mandates Use of 
Pall Corporation Virus Removal Filter
 
    EAST HILLS, N.Y.--(BW HealthWire)--Nov. 12, 1997--Pall 
Corporation (PLL: NYSE) today announced that the Ministry of Public 
Health in China has mandated the use of Pall's Ultipor(R) virus 
removal filter for all China based producers of blood derivative 
products. The announcement came after extensive testing confirmed 
that Pall's Ultipor virus removal filter removed 100% of certain 
large viruses, including the HIV virus which causes AIDS. Pall's 
filter is used with a second viral removal process, and the Ministry 
of Public Health has included this requirement, thus assuring 
compliance with worldwide standard operating procedures.  

    Pall's Ultipor virus removal filter sales in China are expected 
to increase as the market responds to the Ministry's instruction.  
Sales of this product are growing in Europe and North America as 
well. Pall estimates the current worldwide market potential for 
Pall's virus filtration products is $40 million. This is increasing 
as new biopharmaceutical drugs are developed.  

    Eric Krasnoff, Pall Corporation's Chairman and Chief Executive 
Officer, said, "The safety of the blood supply is a critical concern 
throughout the world. Pall Corporation is committed to improving the
quality of transfused blood products. Pall is also the leader in 
filtering white blood cells out of platelets and red cell 
transfusions. White blood cells are known to carry over twenty human
viruses. The announcement in China is an important step forward in 
assuring blood-derived product safety. We expect this technology to
be adopted throughout the world."  

    Validation of the virus removal efficiency of Pall's filter was 
conducted by the National Institute for the Control of Pharm & Bio 
Products (NICOPB) and Research Institute for Microorganism Epidemic 
Disease, Military Medical Academy.  Their results were reviewed and 
unanimously accepted at a national validation meeting which was 
attended by 16 chief officials and experts in biological and virus 
control from key Chinese government agencies and organizations 
including: the Drug Administration of the Ministry of Health, the 
National Class Laboratory of AIDS (NLA), the National Institute for 
the Control of Pharm & Bio Products (NICOPB), The National Vaccine & 
Institute, Beijing Medical University and the National Bio-Products 
Corporation (NBPC) Research Institute for Microorganism Epidemic 
Disease, Military Medical Academy.  

    Pall Corporation, with annual sales over $1 billion, is based in 
East Hills, New York, USA. The Company has the broadest-based 
filtration and separation capabilities in the world. Since 1946, 
Pall Corporation has demonstrated technological leadership and 
offered innovative solutions to complex fluid clarification and 
purification problems in each of its three major markets: Health 
Care, Aeropower and Fluid Processing. The Company employs 8,500 
people at offices and manufacturing facilities throughout the world.
The Company's shares are listed on the New York Stock Exchange (PLL) 
and the London Stock Exchange (0668260). To receive the latest 
information about Pall Corporation, visit Pall's Internet web site at
http://www.pall.com or dial Pall's Select-A-Fax(TM) system at 
1-800-664-PALL.  
     
 
    CONTACT: Peter Cope
             (516) 484-5400
 
END


MSCNFAFAFLEXFAN
Equatorial Palm Oil (LSE:PAL)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Equatorial Palm Oil Charts.
Equatorial Palm Oil (LSE:PAL)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Equatorial Palm Oil Charts.